NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

IPCA LABORATORIES LTD. (BSE: 524494)

 
524494 Technical Analysis
5
As on 24th Dec 2024 524494 SHARE Price closed @ 1582.25 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1106.55 & Strong Buy for SHORT-TERM with Stoploss of 1243.45 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

524494SHARE Price

Open 1582.60 Change Price %
High 1624.90 1 Day -3.35 -0.21
Low 1573.20 1 Week 389.15 32.62
Close 1582.25 1 Month 389.15 32.62
Volume 10904 1 Year 522.00 49.23
52 Week High 1624.90 | 52 Week Low 1053.45
 
BSE INDIA Most Active Stocks
532822 7.47 -0.13%
532411 0.41 0.00%
517001 0.09 12.50%
511700 1.01 -0.98%
512149 0.88 0.00%
511389 7.25 -2.42%
534690 7.65 4.79%
532775 2.04 -0.97%
531328 1.05 0.96%
532648 19.80 -0.60%
 
BSE INDIA Top Gainers Stocks
519200 3.05 281.25%
512063 18.00 200.00%
530905 50.00 194.12%
513630 1.77 86.32%
512559 48.48 20.00%
530883 23.40 20.00%
521234 44.24 19.99%
590074 7.73 15.72%
507864 85.03 14.46%
526544 7.53 14.09%
 
BSE INDIA Top Losers Stocks
513012 0.68 -87.17%
504387 25.70 -76.38%
505658 2.99 -73.93%
509910 22.68 -68.32%
507543 2.58 -30.46%
533102 222.15 -19.99%
506113 134.40 -19.95%
533004 3.35 -18.29%
531838 0.05 -16.67%
533498 90.00 -15.61%
 
 
524494
Daily Charts
524494
Intraday Charts
Whats New @
Bazaartrend
524494
Free Analysis
 
524494 Important Levels Intraday
RESISTANCE1681.88
RESISTANCE1649.93
RESISTANCE1630.18
RESISTANCE1610.43
SUPPORT1554.07
SUPPORT1534.32
SUPPORT1514.57
SUPPORT1482.62
 
524494 Target June 2025
4th UP Target0
3rd UP Target0
2nd UP Target0
1st UP Target0
1st DOWN Target0
2nd DOWN Target0
3rd DOWN Target0
4th DOWN Target0
 
524494 Weekly Target
4th UP Target0.00
3rd UP Target0.00
2nd UP Target0.00
1st UP Target0.00
1st DOWN Target0.00
2nd DOWN Target0.00
3rd DOWN Target0.00
4th DOWN Target0.00
 
524494 Target2025
4th UP Target2060.86
3rd UP Target1756.99
2nd UP Target1569.16
1st UP Target1381.33
1st DOWN Target845.37
2nd DOWN Target657.54
3rd DOWN Target469.71
4th DOWN Target165.84
 
 
524494 Other Details
Segment EQ
Market Capital 263097401344.00
Sector Other
Industry Other
Offical website >
 
524494 Address
524494
 
524494 Latest News
 
Your Comments and Response on IPCA LABORATORIES LTD.
 
524494 Business Profile
Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. It also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic, cardiology, dermatology, diabetes, fever, gastroenterology, hematology, helminthics, hepatoprotective, immunosuppressant, infectious disease, malarial, neurology, nutraceuticals, ophthalmology, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology, as well as products in various dosage forms comprising oral solids, powders for suspension, and liquid and dry injections. The company exports its products to approximately 100 countries worldwide. It has an agreement with Medicines for Malaria Venture to develop a novel antimalarial co-formulation named Atoguanil. The company was incorporated in 1949 and is based in Mumbai, India. Address: 125, Kandivli Industrial Estate, Mumbai, India, 400067
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service